Related Experiment Video
Updated: Aug 22, 2025

Time-lapse Imaging of Primary Preneoplastic Mammary Epithelial Cells Derived from Genetically Engineered Mouse Models of Breast Cancer
Published on: February 8, 2013
Loss of transcription factor EB dysregulates the G1/S transition and DNA replication in mammary epithelial cells
Logan Slade1, Dipsikha Biswas1, Petra C Kienesberger1
1Department of Biochemistry and Molecular Biology, Dalhousie University, Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada.
Abstract:
Triple-negative breast cancer (TNBC) poses significant challenges for treatment given the lack of targeted therapies and increased probability of relapse. It is pertinent to identify vulnerabilities in TNBC and develop newer treatments. Our prior research demonstrated that transcription factor EB (TFEB) is necessary for TNBC survival by regulating DNA repair, apoptosis signaling, and the cell cycle. However, specific mechanisms by which TFEB targets DNA repair and cell cycle pathways are unclear, and whether these effects dictate TNBC survival is yet to be determined. Here, we show that TFEB knockdown decreased the expression of genes and proteins involved in DNA replication and cell cycle progression in MDA-MB-231 TNBC cells. DNA replication was decreased in cells lacking TFEB, as measured by EdU incorporation. TFEB silencing in MDA-MB-231 and noncancerous MCF10A cells impaired progression through the S-phase following G1/S synchronization; however, this proliferation defect could not be rescued by co-knockdown of suppressor RB1. Instead, TFEB knockdown reduced origin licensing in G1 and early S-phase MDA-MB-231 cells. TFEB silencing was associated with replication stress in MCF10A but not in TNBC cells. Lastly, we identified that TFEB knockdown renders TNBC cells more sensitive to inhibitors of Aurora Kinase A, a protein facilitating mitosis. Thus, inhibition of TFEB impairs cell cycle progress by decreasing origin licensing, leading to delayed entry into the S-phase, while rendering TNBC cells sensitive to Aurora kinase A inhibitors and decreasing cell viability. In contrast, TFEB silencing in noncancerous cells is associated with replication stress and leads to G1/S arrest.
Insights
Transcription factor EB (TFEB) is crucial for triple-negative breast cancer (TNBC) survival by controlling DNA replication and cell cycle progression. Inhibiting TFEB impairs TNBC cell proliferation and increases sensitivity to Aurora Kinase A inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Triple-negative breast cancer (TNBC) presents treatment challenges due to a lack of targeted therapies and high relapse rates.
- Transcription factor EB (TFEB) has been identified as essential for TNBC survival, regulating DNA repair, apoptosis, and cell cycle pathways.
- The precise mechanisms by which TFEB influences DNA repair and cell cycle, and their impact on TNBC survival, remain unclear.
Purpose of the Study:
- To elucidate the specific mechanisms through which TFEB regulates DNA repair and cell cycle pathways in TNBC.
- To determine if TFEB's effects on these pathways are critical for TNBC cell survival.
- To investigate the therapeutic potential of targeting TFEB in TNBC.
Main Methods:
- TFEB knockdown was performed in MDA-MB-231 TNBC cells and MCF10A noncancerous cells.
- Gene and protein expression related to DNA replication and cell cycle were analyzed.
- DNA replication was measured using EdU incorporation.
- Cell cycle progression was assessed after G1/S synchronization.
- Origin licensing was evaluated in G1 and early S-phase cells.
- Sensitivity to Aurora Kinase A inhibitors was tested.
Main Results:
- TFEB knockdown decreased expression of genes and proteins involved in DNA replication and cell cycle progression in TNBC cells.
- TFEB silencing reduced DNA replication and impaired G1/S phase transition.
- TFEB knockdown reduced origin licensing in G1 and early S-phase MDA-MB-231 cells.
- TFEB silencing led to replication stress and G1/S arrest in noncancerous MCF10A cells, but not in TNBC cells.
- TFEB knockdown sensitized TNBC cells to Aurora Kinase A inhibitors, decreasing cell viability.
Conclusions:
- TFEB inhibition disrupts cell cycle progression in TNBC by reducing origin licensing and delaying S-phase entry.
- Targeting TFEB enhances the sensitivity of TNBC cells to Aurora Kinase A inhibitors, offering a potential therapeutic strategy.
- TFEB silencing has differential effects on cancer and noncancerous cells, causing replication stress and G1/S arrest in the latter.
Related Concept Videos
Negative Regulator Molecules
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Master Transcription Regulators
DNA Damage can Stall the Cell Cycle
Transcription Factors

